articleNew England Journal of MedicineSep 28, 2019BRONZE OA

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

JLJames LarkinVCVanna Chiarion‐SileniRGRené GonzálezJGJean‐Jacques GrobPRPiotr Rutkowski

Royal Marsden NHS Foundation Trust · Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · +34 more institutions

Indexed incrossrefdatacite

Abstract

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. METHODS We randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo. The two…

Citation impact

3,681
total citations
FWCI
192.66
Percentile
100%
References
14
Citations per year

Authors

31

Topics & keywords

Topics
Keywords
  • Ipilimumab
  • Nivolumab
  • Melanoma
  • Medicine
  • Oncology
  • Internal medicine
  • Metastatic melanoma
  • Immunotherapy
No related works found for this paper.

Funding